The crucial role of L-type Ca 2+ channels in the initiation of cardiac and smooth muscle contraction has made them major therapeutic targets for the treatment of cardiovascular disease. L-type channels share a common pharmacological profile, including high-affinity voltage-and frequency-dependent block by the phenylalkylamines, the benz(othi)azepines, and the dihydropyridines. These drugs are thought to bind to three separate receptor sites on L-type Ca 2+ channels that are allosterically linked. Results from different experimental approaches implicate the IIIS5, IIIS6, and IVS6 transmembrane segments of the α 1 subunits of L-type Ca 2+ channels in binding of all three classes of drugs. Site-directed mutagenesis has identified single amino acid residues within the IIIS5, IIIS6, and IVS6 transmembrane segments that are required for high-affinity binding of phenylalkylamines and/or dihydropyridines, providing further support for identification of these transmembrane segments as critical elements of the receptor sites for these two classes of drugs. The close proximity of the receptor sites for phenylalkylamines, benz(othi)azepines, and dihydropyridines raises the possibility that individual amino acid residues may be required for high-affinity binding of more than one of these ligands. Therefore, we suggest that phenylalkylamines and dihydropyridines bind to different faces of the IIIS6 and IVS6 transmembrane segments and, in some cases, bind to opposite sides of the side chains of the same amino acid residues. The results support the domain interface model for binding and channel modulation by these three classes of drugs. 
INTRODUCTION
The voltage-gated ion channels constitute a large family of heteromultimeric membrane proteins whose functional conformations are sensitive to changes in the electrical potential across the cell membrane. They participate in cellular signaling by permitting the flow of cations down an electrochemical gradient through their pore-forming subunits. Voltage-gated Na + , Ca 2+ , and K + channels share a common architecture and a common set of three voltage-dependent functionally distinct states-closed or resting channels, activated or open channels, and inactivated channels (for review, see 1). Upon depolarization, these channels change from resting to activated states within milliseconds and then inactivate rapidly. Repolarization is necessary to return to the resting state again. These channels differ in their selectivity for permeant cations and in the kinetics and voltage dependence of their transitions among the closed, open, and inactivated states. Voltage-gated Na + and K + channels also differ from voltage-gated Ca 2+ channels in the physiological functions linked to channel opening. Whereas the flow of Na + and K + across cell membranes is mainly linked to alterations in membrane potential, the entry of Ca 2+ into cells through voltage-gated Ca 2+ channels is coupled to many cellular responses, ranging from neurosecretion and muscle contraction to gene expression. Thus, Ca 2+ channels transduce electrical signals in the cell membrane into physiologically significant intracellular Ca 2+ transients. The diversity of cellular responses coupled to Ca 2+ entry through voltagegated ion channels is reflected in the number of distinct gene products that encode voltage-gated Ca 2+ channels. Several types of voltage-gated Ca 2+ channels have been identified electrophysiologically and genetically and have been designated L, N, P/Q, R, and T (for review, see [2] [3] [4] . Although the T-type channel has not yet been characterized at the molecular level, all of the other types of voltage-gated channels consist of a complex of the pore-forming α 1 subunits of 200 to 250 kDa, the disulfide-linked α 2 δ subunits of approximately 140 kDa, and the intracellular β subunits of 55 to 72 kDa, with the exception of the skeletal muscle L-type channel, which also includes a transmembrane γ subunit of 33 kDa (Figure 1 ) (for review, see 5). The α 1 subunits confer the characteristic pharmacology and basic functional properties of each channel type, but their function is modulated by association with the auxiliary subunits. All of the cloned Ca 2+ channel α 1 subunits share a common topology of four homologous domains (I, II, III, and IV), each of which is composed of six putative transmembrane segments (S1-S6) and two short segments (SS1 and SS2) between the S5 and S6 segments. The S4 segments serve as the voltage sensors for channel activation, the SS1 and SS2 segments line the extracellular mouth of the pore of the channel, and the S6 and possibly S5 segments are likely to form most of the pore lining and the intracellular mouth of the pore (Figure 1 ) (reviewed in 1). The L-type Ca 2+ channel α 1 subunits include at least three distinct gene products: skeletal muscle (α 1S ) (6) , cardiac/smooth muscle/neuronal (α 1C ) (7) (8) (9) , and endocrine/neuronal (α 1D ) (10, 11) . The crucial role of the α 1C -containing L-type Ca 2+ channels in the initiation of contraction of cardiac and smooth muscle has made them major therapeutic targets for the treatment of cardiovascular disease. All L-type channels share a common pharmacological profile, with a high sensitivity to several classes of drugs that have been used as selective L-type channel blockers. The three main classes of L-type-selective Ca 2+ channel blockers currently available for clinical use are the phenylalkylamines, the benz(othi)azepines, and the dihydropyridines. These drugs bind to three separate receptor sites on L-type Ca 2+ channels, which are allosterically linked (12, 13) . In this review, we briefly discuss the characteristics of block of L-type Ca 2+ channels by each of these three classes of drugs and then focus primarily on recent advances in our understanding of their receptor sites and the molecular interactions between these drugs and L-type calcium channel α 1 subunits.
PHENYLALKYLAMINES

Structure and Selectivity
Verapamil is the prototype phenylalkylamine and is the only drug of this class currently in clinical use. Verapamil is used to treat hypertension because of its ability to block L-type Ca 2+ channels in vascular smooth muscle; however, unlike dihydropyridines, verapamil is also effective in the treatment of arrhythmias in cardiac muscle (14) . Three compounds within the phenylalkylamine class have been extensively studied. Verapamil, desmethoxyverapamil (also designated D888 or devapamil), and methoxyverapamil (also designated D600 or gallopamil) are structurally very similar (Figure 2) , and all three block Ltype Ca 2+ currents in a variety of cell types. The phenylalkylamines bind to a site on L-type channels with the rank order of affinity desmethoxyverapamil methoxyverapamil > verapamil (15) . All three compounds have a chiral center, and the levorotatory (−) enantiomers are more potent than the dextrorotatory (+) enantiomers (15) . The phenylalkylamine site is allosterically linked to the binding sites for dihydropyridines and benz(othi)azepines such that phenylalkylamine binding inhibits binding of drugs from both of the other classes (12, 13, 16) . Though L-type Ca 2+ channels are most sensitive to phenylalkylamines, other types of Ca 2+ channels (17) , as well as Na + and K + channels (18) (19) (20) (21) , are blocked by phenylalkylamines at higher concentrations.
Voltage and State Dependence of Ca 2+ Channel Block by Phenylalkylamines
The phenylalkylamines bind to the L-type Ca 2+ channel with an apparent affinity that depends on the voltage-dependent conformational changes in the functional state of the channel protein (22) (23) (24) . The characteristics of this voltage-and state-dependent block of Ca 2+ channels by organic Ca 2+ antagonists are consistent with the modulated receptor model first described for local anesthetic block of Na + channels (25, 26) . Plasma membrane depolarization from a negative resting potential (approximately −90 to −60 mV) to positive potentials (0 to +20 mV) causes a transition of Ca 2+ channels from a closed, resting state to an open, Ca 2+ -conducting state or a nonconducting inactivated state. Both binding (27) and electrophysiological (22) (23) (24) (28) (29) (30) (31) studies indicate that these channel states have different affinity for phenylkalkylamines in the order inactivated open > resting. Because the probability that a channel will occupy one of these three states changes with voltage, the affinity for drug binding changes with membrane potential, and the dependence of apparent channel affinity on membrane potential follows a sigmoidal relationship that is a function of the voltage dependence for channel activation and inactivation (24) . This relationship could arise from either a continuous change of affinity with voltage at a static binding site or a voltage-dependent shift in the proportion of channels in low-and high-affinity conformations. Both binding and electrophysiological studies support the conclusion that the voltage dependence of phenylalkylamine affinity arises from voltage-dependent changes in the ratio of resting, open, and inactivated Ca 2+ channels and the resulting state-dependent change in affinity for drug binding. (32) . Rapid binding of phenylalkylamines during depolarizations and slowed recovery of channels during repolarizations result in frequency-dependent enhancement of drug block. This characteristic of the phenylalkylamines is considered to be an important element in their use as antiarrhythmic drugs.
Tonic, or resting, block of Ca 2+ channels is measured from negative membrane potentials with brief, infrequent depolarization. In contrast, frequencydependent block is measured during rapid trains of depolarizations. Different phenylalkylamines give different degrees of tonic and frequency-dependent block, reflecting their different on rates, off rates, and equilibrium binding affinities. Comparing the relative affinities of the three most common phenylalkylamines shows a rank order of desmethoxyverapamil verapamil > methoxyverapamil for tonic block and desmethoxyverapamil > methoxyverapamil > verapamil for frequency-dependent block (33, 34) .
Access Pathway to the Phenylalkylamine Receptor Site
Verapamil and its derivatives are tertiary amines and exist as predominantly positively charged species at physiological pH, but a small percentage of phenylalkylamine molecules remain uncharged under these conditions. Phenylalkylamines block L-type currents when applied extracellularly, but the block could be due to diffusion of uncharged drug molecules across the cell membrane and subsequent binding to an intracellular site. In order to determine which side of the plasma membrane provides the access route for phenylalkylamines to enter their receptor site on L-type channels, quaternary amine derivatives of verapamil (D575), methoxyverapamil (D890), and desmethoxyverapamil (Sz1515) (Figure 2 ), which are permanently charged and therefore membraneimpermeant, were synthesized. When D890 was applied from the extracellular side to isolated ventricular myocytes, it had no effect on action potential plateau or duration, whereas methoxyverapamil applied in the same way decreased action potential plateau and duration in a dose-dependent manner (35) . However, when injected into the cell, both D890 and methoxyverapamil decreased action potential duration, leading to the conclusion that these phenylalkylamines gain access to their binding site from the intracellular side of the cell membrane. Multiple subsequent reports have confirmed block by internally applied quaternary phenylalkylamines (36) (37) (38) (39) . In contrast, a more recent study found that the quaternary derivatives of desmethoxyverapamil, verapamil, and methoxyverapamil were all ineffective during intracellular and extracellular application in ventricular myocytes (40) . Thus, while an intracellular access pathway appears to have been clearly demonstrated in most experiments, more work is needed to resolve these recent apparently contradictory experimental findings.
Biochemical Localization of the Phenylalkylamine Receptor Site
Biochemical approaches have also been employed to define the location of the phenylalkylamine receptor site. The phenylalkylamine receptor site was localized to the α 1 subunit of L-type Ca 2+ channels from skeletal muscle with the use of the photoaffinity label [ 3 H]-LU49888 (41) (Figure 2 ). This compound binds to L-type Ca 2+ channels with an affinity similar to that of desmethoxyverapamil. Structurally, LU49888 has an arylazide moiety in the meta position of the phenylethylamine ring, the same position in which desmethoxyverapamil contains a methoxy group (Figure 2 ). Photoaffinity labeling of skeletal muscle t-tubule membranes or purified skeletal muscle Ca 2+ channels with [ 3 H]-LU49888 resulted in specific derivatization of a 155-kDa protein (41) . The derivatization of this protein by [ 3 H]-LU49888 was completely inhibited in the presence of a low concentration of desmethoxyverapamil, demonstrating the specificity of photolabeling, and the 155-kDa size is characteristic of the Ca 2+ channel α 1S subunit purified from skeletal muscle (42) . With the cloning of the α 1S subunit (6), it became possible to raise antipeptide antibodies against specific stretches of the α 1S polypeptide sequence. The region within the α 1S subunit derivatized by [ 3 H]-LU49888 was further resolved using a battery of such sequence-directed antibodies against regions of α 1S . When [ 3 H]-LU49888-labeled α 1S was proteolytically cleaved, a single radioactive peptide was observed, and this peptide was specifically immunoprecipitated by antibodies to epitopes that bracket transmembrane segment IVS6 (43) . This information, coupled with the size of [ 3 H]-LU49888-labeled peptides generated by several different proteases, led to the conclusion that [ 3 H]-LU49888 derivatized the channel between E1349 and W1391, a peptide that includes all of segment IVS6 and several residues on the C-terminal side of this transmembrane segment ( Figure 3A ). These studies implicated transmembrane segment IVS6 as a critical component of the phenylalkylamine receptor site.
Mutational Analysis of the Phenylalkylamine Receptor Site
Based on the evidence that transmembrane segment IVS6 was involved in phenylalkylamine binding to L-type channels, several studies have further investigated the role of individual amino acids within IVS6. In the first of these studies (44), 17 amino acid residues in IVS6 of the α 1C subunit were individually Figure 3 Localization of the phenylalkylamine and benz(othi)azepine receptor site. (A) Putative membrane folding model for domains III and IV of the L-type Ca 2+ channel α 1 subunit is used to illustrate sites of derivatization by the phenylalkylamine photoaffinity label LU49888 (43) (IVS6 is denoted by double cross hatch, bold lines) and the benzazepine photoaffinity label benziazem (67) (IIIS6 is denoted by single cross hatch, bold lines). The minimal segment of L-type sequence (α 1S ) transferred to P/Q type channel (α 1A ) able to confer increased sensitivity to phenylalkylamines (46) (labeled α 1S in α 1A ) is bracketed. Open circles denote glutamates 1118 and 1419 (numbering according to rat brain α 1C-III sequence). Amino acids within transmembrane segments IIIS6 (B) and IVS6 (C) are involved in phenylalkylamine block. Residues within the rectangular box were scanned, and circled residues disrupted block when mutated to alanine. Dashes indicate amino acid residues that are conserved across all types of voltage gated calcium channels shown. Sequence from the L-type channels from rat brain (α 1C ) (9) and rabbit skeletal muscle (α 1S ) (6) are shown. Alignments show sequence from P/Q type (α 1A ) (120) and N-type (α 1B ) (121) channels for comparison. mutated to alanine, the resulting mutants were expressed in mammalian cells, and the sensitivity of the expressed L-type current to block by desmethoxyverapamil (D888) was assayed (44) . Three of these mutations-Y1463A, A1467S, and I1470A-were found to increase the IC 50 for D888 from 6-to 12-fold. The triple mutant Y1463A, A1467S, I1470A (YAI) had an IC 50 of 5 µM, >100 times that of wild-type α 1C (48 nM) . The three positions mutated in YAI ( Figure 3C ) are not conserved between L-type and non-L-type Ca 2+ channels, and this mutation effectively reduces the affinity of the α 1C channel to that of the N-type channel expressed in the pheochromocytoma cell line PC-12 (44) . A subsequent study using the same approach and experimental system found that the same three amino acid residues are important for block by desmethoxyverapamil and that mutation of other nonconserved residues in IVS6 had no additional effect on affinity for desmethoxyverapamil (45) .
Transfer of L-type amino acid sequences to non-L-type Ca 2+ channels to form chimeras provides an alternative approach to locate regions of the L-type channel involved in phenylalkylamine block. Such chimeric channels should have increased affinity for desmethoxyverapamil if the critical regions of Ltype channels are incorporated into the chimera, because L-type channels are more sensitive to phenylalkylamines than non-L-type channels. Using this approach and channel expression in Xenopus leavis oocytes (46) , it has been shown that transfer of transmembrane segment IVS6 from carp skeletal muscle L-type Ca 2+ channels is sufficient to confer block by relatively high concentrations of desmethoxyverapamil (50 µM) and methoxyverapamil (100 µM). These chimeric substitutions also substantially increased the rate and extent of inactivation of the Ca 2+ channel.
Mutations in Transmembrane Segment IVS6 Specifically Disrupt High-Affinity Phenylalkylamine Binding
Some studies of the phenylalkylamine-binding properties of L-type channels have suggested the existence of two allosterically linked phenylalkylamine receptor sites (47) . In addition, mutations that reduced D888 affinity had no significant effect on block of L-type currents by mibefradil (45), a T-type Ca 2+ channel inhibitor that interacts with the phenylalkylamine site on L-type channels (48, 49) . Recent studies indicate that mutations in transmembrane segment IVS6 have distinct effects on the block of L-type channels by desmethoxyverapamil, verapamil, and methoxyverapamil (34) . The triple mutant YAI in transmembrane segment IVS6 disrupted both resting and depolarized block by desmethoxyverapamil but was relatively ineffective in disrupting resting and depolarized block by verapamil and methoxyverapamil. However, frequencydependent block by all three drugs was substantially reduced in YAI. Kinetic analysis of depolarized block indicated that the on rate was reduced and the off rate increased for desmethoxyverapamil in YAI, but that both on rates and off rates were increased for verapamil and methoxyverapamil. Analysis of these data with a state-dependent model of drug block suggested that the affinity of the inactivated Ca 2+ channel for D888 was reduced by ∼350-fold in YAI, while the affinities of the inactivated states for verapamil and D600 were much less affected (3-fold and 18-fold, respectively). In addition, the YAI residues were found to alter drug access to the receptor site. Taken together, these results show that the YAI mutation effectively eliminates the difference in affinity between desmethoxyverapamil and the lower-affinity drugs verapamil and methoxyverapamil. In addition, the mutation Y1463F substantially disrupted both resting and depolarized block by desmethoxyverapamil, indicating the importance of the hydroxyl group of Y1463 in high-affinity block by desmethoxyverapamil. These results suggest that a hydrogen bond is formed between the proton of the tyrosine hydroxyl of Y1463 and the meta-methoxy phenylethylamine oxygen of desmethoxyverapamil in the drug-receptor complex.
Amino Acid Residues in IIIS6 Are also Involved in Phenylalkylamine Block of L-type Ca 2+ Channels
Although the photoaffinity labeling of transmembrane segment IVS6 by LU49888 led directly to the discovery of the role of individual amino acids within IVS6 in phenylalkylamine block, other regions of importance may not have been identified, because the photoreactive group of LU49888 is located on one end of the drug molecule. Similarly, studies using chimeric channels will not reveal all regions of importance to drug block if the critical amino acids are conserved between the channel types within the chimera. Because transmembrane segment IIIS6 has been shown to be involved in dihydropyridine binding (see below) and phenylalkylamines are allosteric inhibitors of dihydropyridine binding, amino acid residues in IIIS6 may be involved in phenylalkylamine block as well. Alanine-scanning mutagenesis of 18 consecutive amino acid residues in IIIS6 and assay for block of Ca 2+ currents by desmethoxyverapamil revealed that mutation of three amino acids that are conserved between Ltype and non-L-type channels (Y1152, F1164, V1165) and one nonconserved amino acid (I1153) decreased affinity for desmethoxyverapamil 10-to 20-fold ( Figure 3B ) (49) . These results indicate that there are important determinants of phenylalkylamine binding and block in both domains III and IV, consistent with the idea that the drug receptor site is formed at the interface between these domains.
Amino Acid Residues in the Pore Segments which Are Required for High-Affinity Phenylalkylamine Binding
In the modulated receptor model of drug binding and action, the receptor sites for local anesthetics on Na + channels and for phenylalkylamines on Ca 2+ channels are thought to be located in the pore (25, 26) . In Ca 2+ channels, a pair of glutamate residues in the SS2 segments adjacent to S6 in each domain have been implicated in binding of Ca 2+ ions during the transport process (50) (51) (52) . The role of these glutamate residues in binding of phenylalkylamines was investigated because of the predominantly positive charge of the drugs at physiological pH. Mutation of the conserved pore glutamates in domain III or IV ( Figure 3A ) to glutamine resulted in Ca 2+ channels that were 10-to 20-fold less sensitive to block by desmethoxyverapamil, while similar mutations in the pore region of domain I or the extracellular region adjacent to transmembrane segment IVS6 were without effect (49) . Evidently, bound phenylalkylamines make both hydrophobic contacts with residues in transmembrane segments IIIS6 and IVS6 and ionic interactions with the glutamate residues in the pore region.
BENZ(OTHI)AZEPINES
Structure and Selectivity
Diltiazem is the prototype benzothiazepine and is the only drug of this class currently in clinical use. Diltiazem exhibits modest selectivity for block of vascular smooth muscle over cardiac muscle L-type calcium channels, but is also useful in treatment of arrhythmias due to block of L-type channels in heart (14) . Clentiazem (TA-3090), a chloro derivative of diltiazem, has higher affinity for L-type channels than diltiazem ( Figure 4 ) (53, 54) . A series of benzazepines, which differ only slightly in structure from benzothiazepines ( Figure 4 ), have been synthesized and shown to reduce blood pressure in spontaneously hypertensive rats (55) . One benzazepine, SQ32,910, binds to the same site as diltiazem, but with higher affinity (56) . Benz(othi)azepines contain two adjacent chiral centers, and of the four possible diastereomers, the (+) cis isomer is the most potent (57, 58) . The benz(othi)azepine-binding site on L-type calcium channels is allosterically linked to the binding sites for phenylalkylamines and dihydropyridines. Benz(othi)azepine binding inhibits phenylalkylamine binding but stimulates dihydropyridine binding to L-type channels in a temperature-dependent manner (16, 59, 60) . The binding of diltiazem to its receptor on the skeletal muscle Ltype channel is inhibited by calcium ions in the micromolar concentration range (61) . As has been reported for the phenylalkylamines and dihydropyridines, diltiazem is only relatively selective for L-type calcium channels and will block other voltage-gated calcium channels at higher concentrations (17, 62) .
Voltage and State Dependence of Ca 2+ Channel Block by Benzothiazepines: Comparison with Dihydropyridines and Phenylalkylamines
In side-by-side comparisons of the three primary organic Ca 2+ antagonist classes, researchers concluded that benzothiazepines have blocking properties that are intermediate between dihydropyridines and phenylalkylamines (22, 24, 31) . Diltiazem was found to produce more tonic block than methoxyverapamil but less than nifedipine or nitrendipine. During a series of depolarizations, diltiazem was found to produce more frequency-dependent block than the dihydropyridines but less than methoxyverapamil. In a train of depolarizations, the time course of recovery from drug block between depolarizations principally determines the extent of frequency-dependent block, and the recovery time course for diltiazem (τ = 2 s) was found to be intermediate between those of methoxyverapamil (τ = 15 s) and nifedipine (τ = 0.5 s). As with the other Ca 2+ channel antagonists, frequency-dependent block by diltiazem is due to rapid binding to the open state and preferential binding to the inactivated channel. Uehara & Hume (24) noted that both the molecular weight and fraction of charged molecules at physiological pH place diltiazem between methoxyverapamil and nifedipine and may partially explain the rank order of potency.
Access Pathway to the Benz(othi)azepine-Binding Site
Benz(othi)azepine calcium channel blockers contain a tertiary alkylamine side chain that is required for their pharmacological activity (63) . SQ32,428, a membrane-impermeant quaternary amine derivative of SQ32,910 (Figure 4) , has been synthesized (55) and used to determine from which side of the cell membrane benzazepines access their binding site in primary cultures of ventricular myocytes (37) or smooth and skeletal muscle cell lines (56) . In both studies, extracellular application of both the tertiary amine SQ32,910 and the quaternary amine SQ32,428 effectively blocked L-type calcium currents. In contrast, intracellular application of either compound did not result in significant reduction of L-type current, leading to the conclusion that benz(othi)azepines block L-type channels via an extracellular binding domain. Both studies, however, found that SQ32,428 was much less potent than SQ32,910 (IC 50 > 100 times greater), suggesting that the uncharged fraction of tertiary amine compounds that exist at physiological pH may bind preferentially to the channel from outside of the cell.
Biochemical Localization of the Benz(othi)azepine Receptor Site
Biochemical approaches to characterizing the benz(othi)azepine-binding site on L-type calcium channels have made use of several specialized derivatives of these compounds. Radioactive, photoaffinity derivatives of diltiazem (64, 65) , clentiazem (66) , and SQ32,910 (67) (Figure 4 ) have been synthesized, and all have been shown to exclusively and specifically derivatize the α 1 subunit of the skeletal muscle L-type calcium channel. In two of these studies, the photolabeled α 1 subunit was cleaved with proteases, and the specifically derivatized peptides were identified by immunoprecipitation with a set of sequence-directed antipeptide antibodies. In a study using azidobutyrylclentiazem (66) , the site of photolabeling was localized to a region within domain IV of the skeletal muscle L-type calcium channel, but this study was hampered by the low affinity and low incorporation of the photolabel. In a more recent study using a high-affinity benzophenone derivative of SQ32,910 (67) (Figure 4 ), two peptides composed of transmembrane segments IIIS6 and IVS6 and several adjacent amino acids were specifically derivatized and immunoprecipitated, indicating that these two transmembrane segments are part of or adjacent to the benz(othi)azepine-binding site ( Figure 3 ). It has previously been suggested that the benz(othi)azepine site is located in close proximity to the phenylalkylamine receptor site (63) , and these peptide-mapping studies provide direct evidence in favor of that suggestion.
Mutational Analysis of the Benz(othi)azepine-Binding Site
In light of the apparent proximity of the photolabeled regions of the phenylalkylamine and benz(othi)azepine receptor sites noted above, it may be expected that their binding sites might overlap to some extent. In fact, the phenylalkylamineresistant mutant YAI described above (44) ( Figure 3C ) was also found to have an IC 50 for resting block by diltiazem that was 100 times higher than the wild-type channel (GH Hockerman, BZ Peterson, BD Johnson & WA Catterall, unpublished data). A recent paper (67a) demonstrated the importance of the L-type-specific IVS6 amino acid residues Y1463, A1467, and I1470 for benz(othi)azepine block. This study showed that transfer of these amino acids into the corresponding positions in the P/Q-type channel, which is less sensitive to diltiazem than L-type channels, reconstituted L-type sensitivity to diltiazem in the resulting chimeric channel. All three double mutant combinations showed significantly less sensitivity to diltiazem than the triple mutation, indicating a contribution of all three amino acids to diltiazem block. Although the access pathways of phenylalkylamines and benz(othi)azepines to their binding sites appear to be intracellular and extracellular, respectively, the binding sites for these two drug classes may share some common molecular interactions.
DIHYDROPYRIDINES
Voltage and State Dependence of Dihydropyridine Action
The dihydropyridines (DHPs) are allosteric modulators and may act on the L-type Ca 2+ channel as either agonists favoring the open state or antagonists favoring inactivated states (reviewed in 68, 69) . Their specificity of action depends primarily on drug structure, but also on membrane potential, frequency of stimulation, and the resulting channel conformational states. Enantiomeric pairs of DHPs often have very different ratios of agonist and antagonist properties, but even single stereoisomers, such as the agonists (−)-Bay K 8644 and (+)-202-791, can have both agonist and antagonist effects under different experimental conditions (70) (71) (72) (73) . Thus, modulation of Ca 2+ channel activity by DHPs is quite complex and suggests very specific interactions of individual drug molecules with the DHP receptor site.
The affinity for DHP antagonists measured in binding assays with isolated muscle membranes and the affinity measured electrophysiologically in intact muscle tissue differ by 100-to 1000-fold. This difference results from the divergent affinities for the resting and open/inactivated states (23, (74) (75) (76) . Like phenylalkylamines and benzothiazepines, the DHP antagonists bind to the inactivated state of the calcium channel with the highest affinity, resulting in block that is steeply voltage dependent (74) (75) (76) . A particularly striking example of the sharp voltage dependence of dihydropyridine action is found in mRNA splice variants of the human fibroblast L-type channel containing α 1C , in which differences in two amino acid residues in IIIS2 do not alter channel affinity at −40 mV but have a large effect at −90 mV (77) .
DHP agonists also bind preferentially to open/inactivated states that are present at depolarized membrane potentials compared to the resting state present at negative membrane potentials (73) (74, 78, 79) . Ca 2+ channels can function in three gating modes: an inactivated or null mode from which channels do not open upon depolarization (mode 0), a mode in which depolarization elicits multiple short channel openings (mode 1), and a naturally occurring, but usually infrequent, long-opening mode (mode 2). Hess et al (80) proposed that DHP agonists stabilize mode 2 gating and antagonists stabilize mode 0 gating. This simple model accomodates much of the data on DHP agonists, but some results appear to require more complex mechanisms of action (30, (81) (82) (83) . For example, in one study, single-channel open times and other gating properties were found to change continuously with agonist concentration rather than fitting a model for concentration-dependent shift between two modes with fixed gating properties (82 
Identification of the Access Pathway for DHP Binding Using Charged DHPs
Charged DHPs have been used to determine the side from which these drugs gain access to the DHP receptor site. Initially, Kass & Arena (84) used extracellular pH to control the degree of ionization of the tertiary DHP derivative amlodipine, a weak base with a pKa of 8.6 . These experiments demonstrated that the degree of ionization of amlodipine affects the drug's ability to gain access to the DHP receptor site and that extracellular hydrogen ions can interact with the drug-receptor complex. Because the DHP receptor site is accessible to external hydrogen ions, there must be a direct aqueous pathway leading to the DHP receptor site or the receptor must be located on the outer surface of the channel. In a subsequent study, Kass et al (38) studied the block of Ca 2+ channels by intracellular and extracellular application of the ionized form of amlodipine and the permanently charged quaternary DHP derivative SDZ 207-180 ( Figure 5 ). Both charged drugs were found to be ineffective when applied intracellularly, indicating that the DHP receptor site is inaccessible from the intracellular surface. Extracellular application of either compound, however, results in the block of Ca 2+ channels, indicating that DHP antagonists gain access to the receptor site by way of an extracellular pathway.
The neutral DHP agonists (+)-S 202 791 and (−)-Bay K 8644 were also used to demonstrate the sidedness of the DHP receptor site (85) . Intracellular application of these agents was ineffective in stimulating Ca 2+ channel currents. In contrast, a 50-fold lower agonist concentration applied extracellularly stimulated Ca 2+ channel currents. These results suggest that, like antagonists, DHP agonists gain access to their receptor from the outer surface of the cell membrane.
DHPs are lipophilic compounds that have a strong tendency to associate with lipid bilayers, so the DHP receptor site is probably hydrophobic and may be positioned within the lipid bilayer itself (86) . In recent experiments, charged DHPs were used to estimate the depth of the DHP receptor site from the extracellular surface of the cell membrane. Bangalore et al (87) used a series of DHP derivatives in which the DHP ring was linked to a neutral or permanently charged head group and the distance between the head group and the DHP ring was varied by alkyl spacer chains containing 2, 6, 8, 10, 12, or 16 methylene groups. Extracellular application of the neutral derivatives resulted in high-affinity block of Ca 2+ channels regardless of the length of the alkyl spacer chain. In contrast, block by DHP derivatives with charged head groups was highly dependent on the length of the spacer chain, with an optimal length of 10 methylene groups being required for the most potent block. Block by charged DHPs would be independent of spacer chain length if the receptor site was positioned outside the lipid bilayer, so these results indicate that the DHP receptor site is located within the lipid bilayer a distance of 10 methylene groups (approximately 11-14Å) from the extracellular surface of the cell membrane. Intracellular application of DHPs with charged head groups attached to spacer chains up to 16 methylene groups in length failed to block channels, providing additional evidence that the DHP receptor site is located closer to the extracellular surface of the cell membrane and is only accessible from the extracellular surface.
Localization of the DHP Receptor Site Using Photoreactive DHPs
The DHP receptor site can be covalently labeled with photoreactive DHP reagents. Early experiments demonstrated covalent labeling of a 145-to 170-kDa subunit of the Ca 2+ channel with azidopine (88) or PN200-110 (89) ( Figure 5 ). Subsequent studies identified the labeled protein as the α 1 subunit of the skeletal muscle Ca 2+ channel (90) (91) (92) (93) (94) . Several groups have used these photoreactive reagents to localize the DHP receptor site within the α 1 subunit. Initial results with this strategy photolabeled the purified α 1S subunit with the photoreactive DHPs azidopine or nitrendipine, proteolytically digested the resulting complex, purified the photolabeled peptides by reversed-phase HPLC, and determined the amino acid sequence of the major peptides in each labeled fraction by microsequencing (95) . The major peptides sequenced were derived from the hydrophilic intracellular C-terminal region of the α 1S subunit, including amino acids 1390-1399, 1410-1420, and 1428-1437. Minor labeling occurred in the N-terminal intracellular region of the α 1S subunit. The peptide segment including amino acids 1390 to 1437 contains a putative cytosolic Ca 2+ -binding EF-hand region, and the authors speculated that Ca 2+ binding to this region of the channel may be necessary to induce the correct folding of the DHP receptor site. These results were surprising in view of physiological studies with charged DHPs, indicating that DHPs gain access to the receptor site by an extracellular pathway and that the receptor site is located approximately 11-14Å into the lipid bilayer of the cell membrane (38, (84) (85) (86) (87) . It seems unlikely that peptide segments from the intracellular N-and C-terminal domains can form a receptor site that is accessed from the extracellular surface of the channel. It is possible that specifically labeled hydrophobic peptides that comprise the core of the DHP receptor site could not be effectively recovered from the hydrophobic reversed-phase HPLC columns used in this study, and that the hydrophilic peptides that were identified represent nonspecific labeling of sites peripheral to the true DHP receptor site.
Nakayama et al (96) and Striessnig et al (97) also used photoreactive DHP derivatives to identify the regions of α 1S that contain the DHP receptor site and obtained different results. In these studies, α 1S was specifically photolabeled with diazipine (96), azidopine, and PN200-110 (97) and digested with proteolytic enzymes. The resultant labeled peptides were identified by immunoprecipitation with site-directed antipeptide antibodies in the presence of nonionic detergent to solubilize the digested peptides. This method avoids the risk of not recovering hydrophobic peptides from a hydrophobic reversed-phase HPLC column. Three different photolabels with different reaction chemistry and different placement of the photoreactive groups within the drug molecule were used ( Figure 5 ). Diazipine and azidopine contain photoreactive diazirine and phenylazide groups, respectively, which are located on a side chain up to 14.3Å from the DHP ring, the proposed binding center of the ligand. PN200-110 contains a photoreactive benzofurazane group that is intrinsic to the DHP pharmacophore. Amino acid residues on the periphery of the DHP site might be covalently labeled by azidopine and diazipine, while PN200-110 labeling might be more specific for the core of the DHP receptor site.
The predominant site of labeling by all three photoreactive DHPs corresponds to transmembrane segment IIIS6 and a portion of the segment connecting IIIS5 and IIIS6 ( Figure 6A) (96, 97) . The major peptide fragment labeled by PN200-110 contains amino acids 1023-1088 and consists largely of transmembrane segment IIIS6 (97) . Diazipine and azidopine label a fragment consisting of amino acids 988-1022 that contains a segment of the S5/S6 connecting segment of domain III ( Figure 6A) (96, 97) . In addition, approximately 15-30% of the total photolabeling occurred in domain IV in a peptide fragment composed of amino acids 1337-1403 that contained transmembrane segment IVS6 (96, 97) . These same regions of the α 1 subunit were also identified in a more recent study using similar reagents and methods (98) . The differential labeling of adjacent peptide segments in domain III by diazipine and azidopine in comparison to PN200-110 is consistent with the structures of these photoreactive DHPs ( Figure 5 ). It is likely that the long hydrophobic side chains of azidopine and diazirine interact with a subsite in the pore-lining segment of the S5/S6 connecting loop near the core of the DHP receptor site. In contrast, the photosensitive benzofurazane group of PN200-110 is located in close proximity to the DHP ring and would be expected to label a peptide in the core of the DHP receptor site. Taken together, results using photoreactive DHP derivatives suggest that the core of the DHP receptor site is located within transmembrane segment IIIS6 and that S5/S6 linker of domain III and transmembrane segment IVS6 represent regions of the DHP receptor that are important, but more peripheral to the binding center.
Identification of DHP Binding Regions Using Chimeric Ca 2+ Channels
Chimeric Ca 2+ channels were used to identify the peptide segments of the L-type α 1 subunit that contain molecular determinants important for the specificity of the actions of DHP agonists and antagonists on L-type Ca 2+ channels in three studies (45, 99, 100) . Tang et al (99) constructed chimeric channels in which selected portions of domains III and IV of α 1A were substituted into α 1C , and the regions of α 1C required to retain DHP sensitivity were identified. DHP sensitivity was monitored by measuring concentration-dependent block (antagonists) or stimulation (agonists) of ionic currents expressed in Xenopus laevis oocytes during depolarization from a holding potential of −80 mV. No determinants of DHP binding were found in domain III in this study, but evidence was presented for important determinants of high-affininty block by antagonists in domain IV between segments IVS5 and IVS6 and for important determinants of agonist action in transmembrane segment IVS6.
Grabner et al (100) systematically substituted all regions of α 1C or α 1S into α 1A to construct a family of chimeric α 1A Ca 2+ channels, and the regions of α 1C required to reconstitute high affinity for DHPs were identified. Although Tang et al (99) did not identify any important regions in domain III, Grabner et al (100) found two regions of domain III that are important for the action of DHP agonists and antagonists ( Figure 6B, bold and shaded) . One region contains all of IIIS5 and most of the IIIS5-SS2 connecting segment, and the other region consists of the C-terminal portion of IIIS6. The evidence for an essential role of IIIS6 strengthens the conclusion from photoaffinity labeling studies that this region is a component of the core of the DHP receptor site (97). Grabner et al (100) also found that the IVS5-IVS6 connecting segment was important for binding of DHP antagonists and that IVS6 contained determinants required for action of DHP agonists ( Figure 6B, bold and shaded) .
In a more recent study, Schuster et al (45, 101) used a chimeric approach similar to that used by Tang et al but substituted sequences from α 1E and focused entirely on domain IV. Their results contrast with those of Tang et al (99) and Grabner et al (100) . They found that the IVS5-IVS6 connecting segment does not contain molecular determinants required for the actions of either DHP agonists or antagonists, and they found a short segment of transmembrane segment IVS6 that was required for the actions of both antagonists and agonists (45) .
Although there are important differences in the details of the results of these three studies of channel chimeras, some clear conclusions emerge and support the previous conclusions from photoaffinity labeling experiments (96, 97) . First, the results from these studies indicate that all the amino acids responsible for the differences in DHP sensitivity between L-type and non-L-type Ca (96, 97) . Numbers refer to amino acid positions in α 1S that form the boundaries of the photolabeled segments. (B) Bold and shaded regions refer to segments of the receptor site found to be important for the actions of DHPs that were identified using chimeric Ca 2+ channels (99, 100) . Numbers refer to amino acid positions in α 1S that were identified by site-directed mutagenesis and radioligand-binding experiments as being critical for the binding of DHP agonists and antagonists (102, 107) . The largest effects on DHP binding were seen in IIIS6 and IVS6. (C, D) Sequence alignment of transmembrane segments IIIS6 (C) and IVS6 (D) from DHP-sensitive (α 1S , α 1C , α 1D ) and DHP-insensitive (α 1A , α 1B , α 1E ) Ca 2+ channels (6, 7, (121) (122) (123) (124) . Asterisks refer to amino acids in IIIS6 and IVS6 of α 1S that are not conserved between DHP-sensitive and -insensitive channels and were analyzed by radioligand binding (102) . The same positions in IVS6 of α 1C (with the exception of Ile-1460) were analyzed electrophysiologically (45) . Boxes refer to amino acids that were analyzed by alanine scanning mutagenesis and radioligand binding (103) . Circles refer to amino acids found to be critical for the binding and/or actions of DHP agonists and antagonists. chimeras. A weakness of studies of channel chimeras is that large numbers of amino acid residues are substituted in most chimeric replacements. The differences among the results of these three studies presumably arise because complex interactions between the inserted chimeric segments and the surrounding host channel create incompatibilities of structure that are not directly relevant for DHP binding but disrupt local folding of the protein. Analysis of these regions by mutations of single amino acid residues may resolve the apparent discrepancies between these studies of channel chimeras and further focus on the individual amino acid residues that are essential for DHP binding and action.
Identification of Individual Amino Acid Residues Critical for DHP Binding Using Site-Directed Mutagenesis
Based on these photolabeling and chimeric analyses, site-directed mutagenesis was used to alter amino acid residues within the S6 transmembrane segments and the entire S5-S6 connecting loops of domains III and IV in order to identify individual amino acids that are critical determinants of DHP binding (102) . As with the chimeric approaches above, this experimental approach took advantage of the differences in DHP sensitivity between L-type and non-L-type Ca Figure 6C ). Similar analyses of mutations of individual amino acids within IVS6 revealed that the K d values for the mutants Y1365I, M1366F, I1372M, and I1373L were increased from 1.9-to 6.7-fold, respectively ( Figure 6D ).
Schuster et al (45) used a similar approach and found that three amino acids in transmembrane segment IVS6 of α 1C , which corresponded to Y1365, M1366, and I1373 of α 1S , are important for high affinity block by PN200-110. Substitution of the amino acids present in DHP-insensitive channels into these three positions results in a 100-fold decreased sensitivity to PN200-110. The basic electrophysiological properties and the voltage-dependence of drug binding were not altered in these mutant channels, so the 100-fold decrease in DHP sensitivity is probably due to the disruption of the DHP receptor site itself.
The amino acids in IIIS6 of α 1S that were identified by single-residue chimeric mutagenesis to their counterparts in non-L-type Ca 2+ channels (102) flank a tyrosine residue (Y1048) that is conserved between DHP-sensitive and -insensitive Ca channels ( Figure 6C ). Because this tyrosine residue is analogous in position in IIIS6 to the critical residue Y1365 in IVS6, the mutants Y1048F and Y1048A were analyzed to determine whether this conserved residue is an important determinant for DHP binding. The mutant Y1048F has a K d value 12.4-fold higher than that of wild-type mutants, so simply removing the phenolic hydroxyl group from Y1048 has substantial effects on DHP binding. Y1048A exhibits no detectable DHP binding at concentrations of (+)-[
3 H]PN200-110 up to 25 nM, but immunoblots indicate that the protein is expressed well. Failure to observe specific binding at 25 nM ligand concentration indicates that the K d is at least 250 nM. Thus, the alteration of a single amino acid in the mutant Y1048A decreases the affinity of the channel for (+)-[
3 H]PN200-110 by more than 1000-fold. These results are in agreement with photoaffinity labeling experiments, suggesting that the DHP antagonist PN200-110 interacts with amino acid residues in transmembrane segment IIIS6. The magnitude of the effects on DHP binding seen with the mutants Y1048F and Y1048A suggests that the photoreactive benzofurazane group of PN200-110 may react directly with Y1048 in these photoaffinity labeling experiments.
It is interesting that the most critical single amino acid residue identified so far, Y1048, is conserved between DHP-sensitive and -insensitive Ca 2+ channel types (102) . Evidently, conserved amino acid residues are essential for the formation of the high-affinity DHP-binding site in addition to residues that are unique to the DHP-sensitive channels. Alanine-scanning mutagenesis was employed to identify all of the amino acids, both conserved and nonconserved, that are critical determinants for DHP binding in transmembrane segments IIIS6 and IVS6 (103) . In this study, most of the amino acids in IIIS6 and IVS6 of α 1C were systematically changed to alanine, and the resulting mutants were coexpressed with α 2 δ and β 1B in tsA-201 cells. DHP binding affinity was monitored by saturation binding using the radioligand (+)-[ 3 H]PN200-110 and Scatchard analysis. Alanine was chosen for substitution in these experiments because it has minimal effects on protein secondary structure (104) and therefore is expected to reduce the hydrophobicity and size of the amino acid residue in each position in these putative α-helices without causing global conformational changes. Of the mutations in IIIS6, the largest effects were seen when amino acids corresponding to residues I1049, I1052, and M1057 of α 1S were changed to alanine; this resulted in dissociation constants that were larger than those of wild-type mutants by 5-, 11-, and 10-fold, respectively. All three of these residues are unique to DHP-sensitive channels and must play an important role in conferring the differences in DHP sensitivity observed between L-type and non-L-type Ca 2+ channels ( Figure 6C ). In addition, alteration of several conserved residues in α 1C to alanine has large effects on DHP binding. Mutation of the conserved asparagine residue that corresponds to position 1374 in α 1S yields a dissociation constant that is eight-fold greater than that of wild type. Alteration of the amino acid corresponding to Y1048 in α 1S results in a mutant channel that exhibits no detectable DHP binding at concentrations of (+)-[
3 H]PN200-110 up to 25 nM, so the dissociation constant for this mutant channel must be at least 250 nM (Figure 6C, D) .
Together, these mutagenesis results indicate that the core of the receptor site for DHP antagonists is shared between transmembrane segments IIIS6 and IVS6, in agreement with the predictions from photoaffinity labeling studies (96, 97) . I1049, I1052, and M1057 in IIIS6 and Y1365, M1366, I1372, and I1373 in IVS6 are unique to DHP-sensitive channels and probably account for the differences in sensitivity between L-type and non-L-type Ca 2+ channels. In addition to these critical nonconserved residues, Y1048 and N1374 are conserved between DHP-sensitive and -insensitive channels and are essential for high-affinity DHP binding. The amino acid residues in transmembrane segments IIIS6 and IVS6 that are required for high-affinity binding of DHP antagonists are located in nearly analogous positions in the putative α-helices. These results are consistent with the domain-interface model of DHP binding, which suggests that DHP binding between the corresponding faces of these two transmembrane segments in domains III and IV modulates channel gating (105) .
Ca
2+ Binding in the Pore of L-type Ca 2+ Channels Modulates High-Affinity DHP Binding
Although a great deal is now known about the location of the DHP receptor site, comparatively little is known about the molecular mechanism by which DHPs modulate the gating behavior of L-type Ca 2+ channels. The binding of a DHP ligand induces conformational changes that stabilize either the open or inactivated states of the channel, so the key to understanding the mechanism by which DHPs modulate channel gating is to understand the conformational states associated with ligand binding. It has long been known that the DHP receptor site can exist in at least two affinity states and that the high-affinity state for antagonists is stabilized by Ca 2+ binding with a dissociation constant less than 1 µM (106). More recently, site-directed mutagenesis and radioligand binding were utilized to demonstrate that the Ca 2+ -binding site allosterically coupled to the DHP receptor site is located in the pore region of the Ca 2+ channel (107, 108) . The loops that connect transmembrane segments S5 and S6 in each domain contain short SS1/SS2 segments that are thought to form the ion selectivity filter of the Ca 2+ channel (Figure 1 ). Four conserved glutamate residues in the SS2 segments (one from each domain) form two Ca 2+ -binding sites that are essential for ion permeation and selectivity (50) (51) (52) . Each of these negatively charged glutamate residues was replaced by neutral glutamine residues, and the effects of these mutations on Ca 2+ sensitivity were determined by radioligand binding using (+) In general, the effects of divalent cations on DHP binding are biphasic with enhanced binding at intermediate concentrations followed by reduced binding as the concentration of cation is increased. This observation can most easily be explained by a model with a single DHP receptor site that exists in three interconvertible affinity states dependent on the number of cations bound to the channel (see Scheme 1) (106, 107) . Recent results suggest that the high-affinity binding of a single divalent cation (K Me1 = 0.6 µM) shifts the DHP receptor from a low-affinity state (K D0 ) to a high-affinity state (K D1 ), and the binding of a second cation (K Me2 = 100 mM) causes the receptor to enter a very low affinity state (K D2 ).
Permeation of Ca 2+ through the pore of the Ca 2+ channel is thought to require the binding of two Ca 2+ ions (109) (110) (111) . The first Ca 2+ ion binds with a K d of 0.7 µM and blocks the pore, while the second binds with a K d approaching 100 mM and allows permeation (110 
Do DHP Agonists and Antagonists Share the Same Receptor Site?
Radioligand binding and electrophysiological studies have suggested the existence of two DHP receptor sites-a high-affinity site that mediates the antagonist effects and a low-affinity site that mediates agonist effects (112, 113) . More recently, the chimeric studies of Tang et al (99) and Grabner et al (100) suggested that transmembrane segment IVS6 is important for the actions of DHP agonists and not of antagonists. In contrast, other studies have suggested the existence of one DHP receptor site that mediates both the agonist and antagonist effects (106) . This hypothesis is supported by Schuster et al (45) , who found that segment IVS6 is important for the actions of DHP agonists and antagonists and that the agonistic effects are eliminated by altering the residues in α 1C that correspond to Y1365 and M1366 in α 1S ( Figure 6D ). In addition, competition experiments between (+)- [ 3 H]PN200-110 and (−)-Bay K 8644 were used (102) to determine whether the same amino acids that determine antagonist sensitivity also determine the affinity of the channel for DHP agonists. For each of the mutants in domains III and IV analyzed, the increase in K d for the agonist (−)-Bay K 8644 was comparable to that for the antagonist (+)- [ 3 H]PN200-110. Since there are many shared binding determinants for DHP agonists and antagonists, it is likely that these two classes of channel modulators bind to the same receptor site. The distinctive properties of DHP agonists are probably due to stabilizing a specific conformation of the single DHP receptor site through the specific stereochemical interaction with the agonist, rather than by interacting with a different receptor site. The different effects of chimeric substitutions on antagonist and agonist actions may result from effects on the energetic requirements for channel activation by DHPs. This hypothesis is consistent with the finding that the efficacy of channel activation at saturating concentrations of agonist was reduced 4.1-fold in a chimeric channel consisting of the extracellular portion of IVS6 and the IVSS2-IVS6 connecting segment from a non-DHP-sensitive channel (99) . This result indicates that the conformational changes that occur upon ligand binding are disrupted in this chimera, thus making the activation of the channel less favorable rather than altering the intrinsic binding affinity of the agonist. Therefore, these results do not support the hypothesis that there are separate sites for DHP agonists and antagonists.
CONCLUSION
The recent analysis of the receptor sites for Ca 2+ antagonist drugs on L-type Ca 2+ channels has led to the surprising conclusion that the phenylalkylamine, benz(othi)azepine, and dihydropyridine classes of drugs all interact with receptor sites formed by the same general region of the α 1 subunit. Moreover, it appears that local anesthetics and related drugs that block Na + channels interact with an analogous region of their α subunit (114) . The implications of these results for the sites and mechanisms of drug action on these ion channels are considered below.
A Complex Calcium Antagonist Receptor Region Formed by Transmembrane Segments IIIS6 and IVS6
Results from three quite different experimental approaches implicate the IIIS6 and IVS6 transmembrane segments of the α 1 subunits of L-type Ca 2+ channels in drug binding. First, photoaffinity labeling experiments have shown that specifically bound photoreactive derivatives of the phenylalkylamines, benz(othi)azepines, and dihydropyridines can be covalently attached to peptides that include transmembrane segments IIIS6 and IVS6 (43, 67, (96) (97) (98) . In each case, these peptides incorporate a large fraction of the covalent label, and the incorporation is specific by the criterion of competitive inhibition by excess unlabeled drug. In the case of the dihydropyridines, photoreactive probes having three distinct photoreactive moieties with different reactivities label the same two transmembrane segments. These results provide strong evidence for direct interaction of the phenylalkylamines, benz(othi)azepines, and dihydropyridines with the IIIS6 and IVS6 transmembrane segments of the α 1 subunits of L-type Ca 2+ channels. The IIIS6 and IVS6 transmembrane segments are also implicated in the selectivity of block of L-type Ca 2+ channels by these drugs. Chimeric Ca 2+ channels constructed from complementary segments of L-type and non-L-type α 1 subunits require the IVS6 segment of L-type channels for high-affinity phenylalkylamine and benzothiazepine binding and both the IIIS6 and IVS6 segments for high-affinity DHP binding (45, 46, 67a, 99, 100) . These results provide further strong support for identification of the IIIS6 and IVS6 transmembrane segments as essential components of the receptor sites for all three classes of drugs and demonstrate their role in determining the unique high affinity of L-type Ca 2+ channels for these drugs.
Site-directed mutagenesis has identified single amino acid residues within the IIIS6 and IVS6 transmembrane segments that are required for high-affinity binding of phenylalkylamines, benzothiazepines, and/or DHPs, providing further support for identification of these transmembrane segments as critical elements of the receptor sites for these two classes of drugs (44, 45, 67a, 102, 103) . Site-directed mutagenesis of three amino acid residues in L-type Ca 2+ channels to their identity in non-L-type Ca 2+ channels is sufficient to reduce the affinity for desmethoxyverapamil and diltiazem to that observed for non-Ltype Ca 2+ channels (44, 67a) . Both L-type-specific and conserved amino acid residues are required for high-affinity binding of both phenylalkylamines and DHPs, indicating that both common structural features of the IIIS6 and IVS6 transmembrane segments and structural features that are unique to L-type Ca 2+ channels are required for high-affinity binding.
Interactions with Common and Unique Amino Acid Residues in Binding of Ca 2+ Antagonist Drugs
Ligand-binding studies indicate that the phenylalkylamines, benz(othi)azepines, and DHPs bind to three separate receptor sites, which interact allosterically. This requires that all three classes of drugs be able to occupy their receptor sites simultaneously. Consistent with this expectation, we have found some amino acid residues in both transmembrane segments IIIS6 and IVS6 that are required for the binding of either phenylalkylamines (Figure 7 , black diamonds) or DHPs ( Figure 7 , black circles) but not both. The close proximity of the receptor sites for phenylalkylamines, benz(othi)azepines, and DHPs raises the possibility that individual amino acid residues may be required for high-affinity binding of more than one of these ligands. In agreement with this expectation, we have identified amino acid residues that are required for high-affinity binding of both classes of drugs ( Figure 7 , black squares). How can these findings be accommodated with the earlier results indicating separate binding sites for phenylalkylamines and DHPs? Phenylalkylamines are considered to be pore-blocking drugs that block Ca 2+ channels directly by occluding the transmembrane pore through which Ca 2+ ions move. In contrast, DHPs bind to a single site at which agonists increase Ca 2+ channel activity and antagonists reduce Ca 2+ channel activity, so they cannot bind in a manner that blocks the pore. Instead, DHP antagonists appear to block the pore indirectly by stabilizing a channel state with a single Ca 2+ ion bound in a blocking position in the pore (107) . Therefore, we suggest that phenylalkylamines and DHPs bind to different faces of the IIIS6 and IVS6 transmembrane segments and, in some cases, bind to opposite sides of the side chains of the same amino acid residues (Figure 7) . In this way, single amino acid residues may contribute to formation of the distinct binding sites of two different classes of drugs that interact allosterically. In this model, the allosteric interactions between bound phenylalkylamines and DHPs would take place over very short distances, possibly separated by no more than the plane of a phenyl ring or the width of an aliphatic side chain of single amino acid residues.
A Domain-Interface Model for Allosteric Modulation of L-type Ca
2+ Channels by Calcium Antagonist Drugs
All three classes of Ca 2+ antagonist drugs are allosteric ligands whose binding is state-dependent and is influenced in a reciprocal manner by binding of the other classes of Ca 2+ antagonists to distinct but interacting sites. Their effects on Ca 2+ channel function and their interactions with each other are similar to the actions of allosteric effectors on enzymes. In most cases that are well studied, binding of allosteric effectors to enzymes is thought to take place at subunit interfaces (115) (116) (117) . Similarly, strong evidence now indicates that the agonists of pentameric nicotinic acetylcholine receptors bind at sites that are formed at the interfaces of the α subunits with the β and δ subunits (118) . Thus, there is increasingly strong precedent for binding of allosteric ligands at structural interfaces, possibly because the structure of multimeric proteins is most flexible in those regions. Based on earlier photoaffinity labeling results implicating the IIIS6 and IVS6 transmembrane segments in binding of DHPs, it was proposed that Ca 2+ antagonist drugs act in a similar manner at the interfaces between the homologous domains of the α 1 subunit rather than at the interface between separate subunits (105) . This domain interface model of allosteric drug action can now be generalized to the phenylalkylamine and benz(othi)azepine receptor sites and the DHP receptor site based on the research reviewed here. All three classes of Ca 2+ antagonist drugs interact with receptor sites formed by the IIIS6 and IVS6 transmembrane segments and are therefore well positioned to alter protein-protein interactions at the interface between domains III and IV. Thus, the modulation of Ca 2+ channel function by Ca 2+ antagonist drugs may have an analogous structural basis as the regulation of allosteric enzymes by their effectors.
Analogy to Local Anesthetic Block of Na
+ Channels
Local anesthetics and related antiarrhythmic and anticonvulsant drugs are statedependent pore blockers of Na + channels. Analysis of their receptor site by site-directed mutagenesis has identified three amino acid residues in transmembrane segment IVS6 that are required for high-affinity drug binding and effective frequency-dependent block of the channel (114) . These amino acid residues are in analogous positions to the YAI motif in the IVS6 segment of L-type Ca 2+ channels, which is required for high-affinity binding of the desmethoxyverapamil and diltiazem (44) . Thus, all of the major clinically used drugs that block Na + channels or Ca 2+ channels in a state-dependent manner interact with the IVS6 segments of these channels. This is a remarkable confluence of binding sites for drugs with a wide range of structures. Evidently, these drugs interact with complex overlapping binding sites that alter the properties of the ion channels in a similar manner. Further elucidation of the detailed mechanisms of interaction of these drugs with their receptor sites may reveal the common mechanisms through which they influence Na + and Ca 2+ channel function.
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